Andreas Eugen Busch
Andreas Eugen Busch is on the board of Max-Delbrück-Centrum für Molekulare Medizin (MDC), Absci Corp. and Centogene NV and Chief Scientific Officer at Cyclerion Therapeutics, Inc.
In his past career Dr. Busch was Chief Scientific Officer & Executive VP at Shire Plc, Executive VP & Head-Global Drug Discovery at Bayer HealthCare AG, Head-Global Drug Discovery at Bayer Pharma AG, Head-Cardiovascular Research at Aventis Pharma AG, Head-Cardiovascular Research at Hoechst Marion Roussel, Inc., Global Head-Cardiovascular Research at Sanofi-Aventis Groupe SA and Professor at Johann Wolfgang Goethe-Universität Frankfurt am Main.
Andreas Eugen Busch received a doctorate from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Transactions
Date
Transaction
Value
| 11/09/2020 | 125,000 | Acquisition at $2.53 per share. | 316,250 |
| 11/15/2019 | 125,000 | Acquisition at $1.82 per share. | 227,500 |
